Population PKPD of voclosporin in renal allograft patients
- 30 November 2013
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 54 (5) , 537-545
Abstract
The aims of this population‐pharmacokinetic/pharmacodynamic (POP‐PKPD) analysis of voclosporin in renal allograft patients were to build a POP‐PKPD model for voclosporin and calcineurin activity (CNa) and identify clinically relevant covariates that could assist dosing of the drug. POP‐PKPD modeling was performed using a stochastic approximation of the standard expectation maximization (SAEM) algorithm for nonlinear mixed‐effects as implemented in Monolix™ 3.2. Voclosporin whole blood concentrations were obtained from de novo renal allograft patients and assayed using a validated LC/MS/MS assay. CNa was measured using a 32P‐radiolabeled assay. A two‐compartment model with simultaneous sigmoid inhibitory Emax model was used to describe the PKPD relationship between voclosporin concentration and CNa. The POP‐PKPD model was then utilized to simulate an optimal initial dosing strategy. Eighty‐seven patients were included in the POP‐PKPD study. Population mean estimates (relative standard error, rse) for oral clearance (CL/F) and first compartment volume of distribution (V1), were 717 mL min−1 (35%) and 2010 mL (17%), respectively. Maximum CNa Inhibition (Imax), effective concentration (C50), and baseline immunosuppression (S0) were 0.87 pmol/min/mg (8.0%), 123 ng/mL (10%), and 1.15 pmol/min/mg (4.0%), respectively. Covariate analyses demonstrated that age and body surface area significantly influenced CL/F: , while serum triglycerides significantly altered S0: .Keywords
This publication has 21 references indexed in Scilit:
- The PROMISE Study: A Phase 2b Multicenter Study of Voclosporin (ISA247) Versus Tacrolimus in De Novo Kidney TransplantationAmerican Journal of Transplantation, 2011
- Structural basis for the cyclophilin A binding affinity and immunosuppressive potency ofE-ISA247 (voclosporin)Acta Crystallographica Section D Structural Biology, 2011
- Novel inhibitors of the calcineurin/NFATc hub - alternatives to CsA and FK506?Cell Communication and Signaling, 2009
- Development and validation of a LC/MS/MS method for quantifying the next generation calcineurin inhibitor, voclosporin, in human whole bloodJournal of Chromatography B, 2008
- Calcineurin/NFAT signalling regulates pancreatic β-cell growth and functionNature, 2006
- Immunosuppression: Evolution in Practice and Trends, 1994–2004American Journal of Transplantation, 2006
- Sirolimus in Combination with Tacrolimus Is Associated with Worse Renal Allograft Survival Compared to Mycophenolate Mofetil Combined with TacrolimusAmerican Journal of Transplantation, 2005
- In vivo evaluation of the novel calcineurin inhibitor ISATX247 in Non-Human primatesThe Journal of Heart and Lung Transplantation, 2003
- Inhibition of Human Insulin Gene Transcription by the Immunosuppressive Drugs Cyclosporin A and Tacrolimus in Primary, Mature Islets of Transgenic MiceMolecular Pharmacology, 2003
- Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A.Proceedings of the National Academy of Sciences, 1992